Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

229.46 -5.39 (-2.30%)
Streaming Delayed Price Updated: 3:19 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243,469
Open 234.81
Bid (Size) 229.22 (4)
Ask (Size) 229.99 (4)
Prev. Close 234.85
Today's Range 228.63 - 235.28
52wk Range 119.76 - 299.98
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Madrigal Pharmaceuticals Stock a Buy?
It's not the most prominent biotech, but it has an important claim to fame. 
Via The Motley Fool
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+1.14%
+1.14%
1 Month
+5.07%
+5.07%
3 Month
-7.68%
-7.68%
6 Month
+17.33%
+17.33%
1 Year
-10.20%
-10.20%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
2 Under-the-Radar Growth Stocks to Consider
Via The Motley Fool
1 No-Brainer Growth Stock to Buy Now
Via The Motley Fool
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
Via The Motley Fool
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Via InvestorPlace
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in April 2024
Via InvestorPlace
2 Top Biotech Buyout Candidates
Via Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
Via Investor Brand Network
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Via The Motley Fool
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Via The Motley Fool
Exposures Product Safety
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Via The Motley Fool
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
Via Benzinga
Exposures Product Safety
Why Is Geron (GERN) Stock Up 94% Today?
Via InvestorPlace
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.